<DOC>
	<DOCNO>NCT00986167</DOCNO>
	<brief_summary>This study multi-site study examine use Quetiapine XR psychotic aggression acute psychiatric setting . The study aim demonstrate management Quetiapine XR significantly reduce aggressive behaviour acute patient psychosis , significantly reduce psychotic symptom decrease requirement sedation use benzodiazepine .</brief_summary>
	<brief_title>Quetiapine Extended Release ( XR ) Management Psychotic Aggression Agitation Adult Acute Psychiatry</brief_title>
	<detailed_description>Aggression common occurrence acute psychiatry experience schizophrenia relate psychotic symptom significantly increase risk aggressive behaviour . This detrimental effect provision therapy safety staff patient . Current practice manage aggression acute psychiatry often involve addition sedate antipsychotic benzodiazepine main atypical antipsychotic continue primary treatment . Quetiapine IR ( immediate release ) find effective treatment management schizophrenia . Quetiapine act brain cell receptor serotonin ( chemical produce brain ) bind . Serotonin propose play significant role impulsive aggression . Additionally , sedation side effect Quetiapine , may also facilitate use aggression . However , Quetiapine commonly use management aggression acute psychiatry due amount time require achieve optimal dose ( 5 day ) . Quetiapine XR ( extended release ) extend release formulation Quetiapine initiate high dose , therapeutic dose achieve rapidly take per day instead twice . This study multi-site study examine use Quetiapine XR psychotic aggression acute psychiatric setting . The study aim demonstrate management Quetiapine XR significantly reduce aggressive behaviour acute patient psychosis , significantly reduce psychotic symptom decrease requirement sedation use benzodiazepine . The participant in-patients experience psychotic aggression ( determined psychiatrist ) . For patient experience aggression ( severe enough require intramuscular injection ) , treat clinician make decision whether treat Quetiapine XR . Those patient meet inclusion/exclusion criterion observe 8 day use measure rate symptom , aggression possible side effect ( include observation , questionnaire review patient file ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Males Females age 1865 year ; 2 . Determined psychiatrist experience acute psychotic symptom ( include mania psychotic feature druginduced psychosis ) ; 3 . Determined psychiatrist act aggressively ( score &gt; 1 OAS ) ; 4 . Inpatient status enrollment ; 5 . Patient agreement take oral medication ; 6 . Provision write informed consent consider able provide consent treat team ; 7 . Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrollment . 1 . Pregnancy lactation ; 2 . Any DSMIV Axis I disorder define inclusion criterion ; 3 . Patients , opinion investigator , pose imminent risk suicide danger self others ; 4 . Known intolerance lack response quetiapine fumarate atypical psychotic , judge investigator ; 5 . Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir ; 6 . Use follow cytochrome P450 inducer 14 day precede enrolment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid ; 7 . Administration depot antipsychotic injection within one dose interval ( depot ) prior recruit trial ; 8 . Patients receive treatment antipsychotic Seroquel XR ( either IM oral ) within one dose interval prior recruit trial ; 9 . Patients receive treatment mood stabiliser antidepressant medication within 7 day prior treatment Seroquel XR ; 10 . Substance alcohol abuse dependence enrolment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion ; 11 . Medical condition would affect absorption , distribution , metabolism , excretion study treatment ; 12 . Unstable inadequately treated renal , hepatic , cardiovascular , respiratory , cerebrovascular , serious progressive physical disease judge investigator ; 13 . Involvement plan conduct study ; 14 . Previous enrolment present study ; 15 . Participation another drug trial within 4 week prior enrolment study long accordance local requirement ; 16 . A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrolment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % ; Admitted hospital treatment DM DM relate illness past 12 week ; Not physician care DM ; Physician responsible patient 's DM care indicate patient 's DM control ; Physician responsible patient 's DM care approve patient 's participation study ; Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomisation . For thiazolidinediones ( glitazones ) period le 8 Weeks ; Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week . 17 . An absolute neutrophil count ( ANC ) &gt; 1.5 x 109 per liter ; 18 . Refusal take oral medication intramuscular antipsychotic medication administer instead .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Psychosis</keyword>
	<keyword>Aggression</keyword>
	<keyword>Acute</keyword>
	<keyword>Quetiapine XR</keyword>
</DOC>